A Pharmacokinetic And Pharmacogenetic Study of Capecitabine in Colorectal Cancer Patients Among South Indian Population

3. AIM AND OBJECTIVE

AIM

To investigate and identify the factors that explain the variability in safety and efficacy of capecitabine in colorectal cancer patients

OBJECTIVE(S)

- To describe the main toxicities observed with the therapy
- To evaluate the possible association of polymorphism of genes (TS, MTHFR, DPD) involved with toxicity/response.
- To characterise the pharmacokinetics of capecitabine and its metabolite
- To develop a population pharmacokinetic model